Substitute - Page 11 of 14 - Express Pharma

‘’Drug price controls aren’’t the only solution’’

‘’Adverse impact of DPCO will be significant on OPPI member companies’’

‘‘The paradigm shift from cost-based pricing to market-based pricing has been long overdue’’

‘A win-win policy for all stakeholders’

‘’DPCO 2013 will equally affect domestic as well multinational pharma companies’’

‘’Longer-term growth prospects’’

‘‘This pricing policy would help on affordability issue’’

‘It would be too early to call this policy a boon or bane’

‘Government should also focus on affordability and access’

‘’It only takes 2.1 treatment errors to convert a TB patient into an MDR patient’’